Ocular Therapeutix (OCUL) Gross Profit (2014 - 2026)

Ocular Therapeutix's Gross Profit history runs 13 years deep, the most recent figure standing at $9.5 million for Q1 2026.

• On a quarterly basis, Gross Profit changed 0.21% year-over-year to $9.5 million in Q1 2026; TTM through Mar 2026 was $45.4 million, a 16.06% decrease from a year earlier, with the FY2025 full-year figure at $45.4 million, down 21.89% from the prior year.
• Gross Profit retreated to $9.5 million in Q1 2026 per OCUL's latest filing, from $11.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $15.9 million in Q4 2024 and bottomed at $9.4 million in Q1 2025.
• The 5-year median for Gross Profit is $12.8 million (2025), against an average of $12.5 million.
• Across the five-year window, Gross Profit surged 84.29% in 2022 and decreased 29.83% in 2025, its largest moves.
• Year by year, Gross Profit stood at $13.1 million in 2022, then grew by 2.69% to $13.4 million in 2023, then gained by 18.17% to $15.9 million in 2024, then fell by 26.47% to $11.7 million in 2025, then dropped by 18.87% to $9.5 million in 2026.
• Per Business Quant, the three latest OCUL Gross Profit figures stand at $9.5 million (Q1 2026), $11.7 million (Q4 2025), and $12.8 million (Q3 2025).